Measuring symptom response to pharmacological interventions in patients with COPD: a review of instruments used in clinical trials

References

• Friedman M, Hilleman DE. Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options. Pharmacoeconomics 2001;19:245–54
   PubMed Web of Science ®Google Scholar
• Rutten van-Mölken MP, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands. Pharmacoeconomics 2001;19\(Suppl. 2):1–6
   Google Scholar
• Murray CJ, Lopez AD. Evidence-based health policy – lessons from the Global Burden of Disease Study. Science 1996;274:740–3
   PubMed Web of Science ®Google Scholar
• Marin JM, Montes de Oca M, Rassulo J, et al. Ventilatory drive at rest and perception of exertional dyspnea in severe COPD. Chest 1999;115:1293–300
   PubMed Web of Science ®Google Scholar
• Foglio K, Carone M, Pagani M, et al. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. Respir Med 2000;94:256–63
   PubMed Web of Science ®Google Scholar
• Milic-Emili J. Inspiratory capacity and exercise tolerance in chronic obstructive pulmonary disease. Can Respir J 2000;7:282–5
   PubMedGoogle Scholar
• Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes: the example of health-related quality of life – a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002;36:209–38
   Web of Science ®Google Scholar
• Santanello NC, Baker D, Cappelleri JC, et al. Regulatory issues for health-related quality of life – PhRMA Health Outcomes Committee Workshop, 1999. Value Health 2002;5:14–25
   PubMedGoogle Scholar
• Wiklund I. Regulatory aspects of quality of life measurement. ESRA Rapporteur 1994;1:20–3
   Google Scholar
• Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000;9:887–900
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12
   PubMedGoogle Scholar
• Anzueto A, Jubran A, Ohar JA, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. J Am Med Assoc 1997;278:1426–31
   PubMed Web of Science ®Google Scholar
• Ayers ML, Mejia R, Ward J, et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J 2001;17:1132–7
   PubMed Web of Science ®Google Scholar
• Boothman-Burrell D, Delany SG, Flannery EM, et al. The efficacy of inhaled corticosteroids in the management of nonasthmatic chronic airflow obstruction. New Zealand Med J 1997;110:370–3
   Google Scholar
• Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998;53:477–82
   Google Scholar
• Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815–21 [erratum in: Eur Respir J 1997;10:1696]
   Google Scholar
• Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480–5
   PubMed Web of Science ®Google Scholar
• Cogo R, Raschi S, Quattrone P, et al. Clinical and histologic rating of treatment with acefyllinate of ambroxol in patients with chronic bronchitis. Adv Ther 1995;12:54–61
   Web of Science ®Google Scholar
• Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med 1996;100(Suppl. 1A):11S–18S
   Google Scholar
• Collet JP, Shapiro P, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. Am J Respir Crit Care Med 1997;156:1719–24
   Google Scholar
• The COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514–21
   PubMed Web of Science ®Google Scholar
• Cook D, Guyatt G, Wong E, et al. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:85–90
   PubMed Web of Science ®Google Scholar
• Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635–9
   PubMed Web of Science ®Google Scholar
• de Jong JW, Koëter GH, van der Mark TW, et al. Effects of cessation of terbutaline treatment on airway obstruction and responsiveness in patients with chronic obstructive pulmonary disease. Thorax 1996;51:684–8
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Morici G, Drago A, et al. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease [SLMT02 Italian Study Group]. Clin Ther 1998;20:1130–48
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119: 1347–56
   Google Scholar
• Friedman M. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. Am J Med 1996;100(Suppl 1A):30S–39S
   Google Scholar
• Kaushik ML, Kashyap S, Bansal SK, et al. Effectiveness of salmeterol in stable COPD. Indian J Chest Dis Allied Sci 1999;41:207–12
   PubMedGoogle Scholar
• Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957–65
   PubMed Web of Science ®Google Scholar
• Man GC, Champman KR, Ali SH, et al. Sleep quality and nocturnal respiratory function with once-daily theophylline (Uniphyl) and inhaled salbutamol in patients with COPD. Chest 1996;110:648–53
   PubMed Web of Science ®Google Scholar
• Martin RJ, Bartelson BL, Smith P, et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999;115:1338–45
   PubMed Web of Science ®Google Scholar
• Meister R, Wittig T, Beuscher N, et al. Efficacy and tolerability of myrtol standardized in long-term treatment of chronic bronchitis. A double-blind, placebo-controlled study [Study Group Investigators]. Arzneimittelforschung 1999;49:351–8
   Google Scholar
• Melani AS, Di Gregorio A. Four-week nebulized beclomethasone dipropionate in stable COPD patients with exertional dyspnoea. Monaldi Arch Chest Dis 1999;54:224–7
   PubMedGoogle Scholar
• Nishimura K, Koyama H, Ikeda A, et al. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995;107:718–23
   PubMed Web of Science ®Google Scholar
• Nishimura K, Koyama H, Ikeda A, et al. The effect of high-dose inhaled beclomethasone dipropionate in patients with stable COPD. Chest 1999;115:31–7
   PubMed Web of Science ®Google Scholar
• O’Brien A, Russo-Magno P, Karki A, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001;164:365–71
   PubMed Web of Science ®Google Scholar
• Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease [International COPD Study Group]. Lancet 1998;351:773–80 [erratum in Lancet 1998;351:1968]
   Google Scholar
• Pela R, Calcagni AM, Subiaco S, et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 1999;66:495–500
   PubMed Web of Science ®Google Scholar
• Poole PJ, Brodie SM, Stewart JM, et al. The effects of nebulised isotonic saline and terbutaline on breathlessness in severe chronic obstructive pulmonary disease (COPD). Aust New Zealand J Med 1998;28:322–6
   PubMedGoogle Scholar
• Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1877–80
   Google Scholar
• Renkema TE, Schouten JP, Koëter GH, et al. Effects of long-term treatment with corticosteroids in COPD. Chest 1996;109:1156–62
   Google Scholar
• Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087–92
   PubMed Web of Science ®Google Scholar
• Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score or sputum properties in patients with stable chronic bronchitis. Chest 1996;109:348–52
   Google Scholar
• Rutten-van Mölken M, Roos B, Van Noord JA. An empirical comparison of the St George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999;54:995–1003
   Google Scholar
• Senderovitz T, Vestbo J, Frandsen J, et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease [The Danish Society of Respiratory Medicine]. Respir Med 1999:93:715–18
   PubMed Web of Science ®Google Scholar
• Ström K, Boman G, Pehrsson K, et al. Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. Eur Respir J 1995;8: 425–9
   Google Scholar
• Tashkin DP, Bleecker E, Braun S, et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med 1996;100(Suppl. 1A):62S–69S
   Google Scholar
• Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995;50:750–4
   PubMed Web of Science ®Google Scholar
• van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878–85
   PubMed Web of Science ®Google Scholar
• van Schayck CP, Dompeling E, van Herwaarden CLA, et al. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomized controlled study. Br J Gen Pract 1995;45:239–44
   PubMed Web of Science ®Google Scholar
• Vecchiet L, Pieralisi G, Ambrosi L, et al. Inhaled beclomethasone dipropionate administered through a new spacer device: a controlled clinical study. Adv Ther 1996;13:335–46
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819–23
   PubMed Web of Science ®Google Scholar
• Weir DC, Bale GA, Bright P, et al. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin Exper Allergy 1999;29:(Suppl 2):125–28
   PubMed Web of Science ®Google Scholar
• ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661–70
   PubMed Web of Science ®Google Scholar
• Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283–9
   PubMed Web of Science ®Google Scholar
• Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377–81
   PubMed Web of Science ®Google Scholar
• Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1984;85:751–8
   Google Scholar
• Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580–6
   PubMed Web of Science ®Google Scholar
• Mahler DA, Jones PW. Measurement of dyspnea and quality of life in advanced lung disease. Clin Chest Med 1997; 18:457–69
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new quality of life instrument. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. New York: Raven Press Ltd; 1995. p. 49–56
   Google Scholar
• Ståhl E. Correlation between objective measures of airway calibre and clinical symptoms in asthma: a systematic review of clinical studies. Respir Med 2000;94:735–41
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary]. Am J Respir Crit Care Med 2001;163:1256–76
   PubMedGoogle Scholar
• van Der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health and Qual Life Outcomes 2003;1:13
   PubMedGoogle Scholar
• Leidy NK, Rennard SI, Schmier J, et al. The breathlessness, cough and sputum scale: the development of empirically based guidelines for interpretation. Chest 2003;124:2182–91
   PubMed Web of Science ®Google Scholar